Press Release
13 September 2023 08:55:00 CEST

Final Clinical Study Report received for PulmoStem Phase Ib clinical trial

Amniotics AB (publ) (Nasdaq Stockholm: AMNI) today announces the company has received the finalized clinical study report for the Phase Ib clinical trial of the cell therapy product candidate PulmoStem which was evaluated in patients with severe lower airway infections caused by Covid-19, Influenza A, and RS-virus. The report confirms the previously announced positive topline results for safety and tolerability.

The primary objective of the study was to evaluate the safety and tolerability of intravenous dosing of PulmoStem in patients with severe lower respiratory tract infections such as Covid-19, influenza A, and RS virus. The study also included secondary and exploratory endpoints related to lung regeneration, biomarkers of inflammatory response, and other clinical endpoints. The study was an adaptive and dose-escalating study that included 6 hospitalized patients with Covid-19 or other lower respiratory tract infections and was conducted at a clinic in Sweden.

The company will, together with the physicians and researchers involved in the study, analyze the results and present the findings in a scientific journal.
-We are pleased to receive the final clinical study report. Study data analysis on how an inflammatory response in the lung can be modulated will help drive our future development of PulmoStem, says Marcus Larsson, CEO, Amniotics AB.

About PulmoStem™

PulmoStem is a neonatal lung-specific mesenchymal stem cell product. PulmoStem is expected to be efficacious in various acute and chronic lung diseases through modulation of the immune response and anti-fibrotic capabilities. The first-in-human clinical study with PulmoStem was completed in hospitalized patients suffering from severe lower respiratory tract infection due to COVID-19, Influenza A, and Respiratory Syncytial Virus (RSV), which can lead to Acute Respiratory Distress Syndrome (ARDS). PulmoStem is also being investigated for lung transplantation treatment and chronic lung-disease e.g. Idiopathic Pulmonary Fibrosis (IPF).

For more information please contact

Marcus Larsson
CEO, Amniotics AB
Phone: +46 (0) 763 0840 91
Email: ml@amniotics.com

About Amnioitics

Amniotics AB (publ) is a clinical stage biotech company, developing innovative therapies, based on amniotic fluid derived stem cells. The company develops therapies to treat diseases where effective treatments are currently lacking.
Amniotics has an established GMP-facility, approved and licensed by the Swedish Medical Products Agency. The company has capabilities as a Contract Development and Manufacturing Organization (CDMO) for other biotech companies.
Amniotics is headquartered in Lund, Sweden.
The company is listed at Nasdaq First North Growth Market in Stockholm. Amniotics Certified Adviser at First North is Redeye AB, e post: certifiedadviser@redeye.se.
Learn more at www.amniotics.com.

Attachments

Final Clinical Study Report received for PulmoStem Phase Ib clinical trial